9TD Stock Overview
A clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Arctic Bioscience AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.15 |
| 52 Week High | NOK 1.23 |
| 52 Week Low | NOK 0.089 |
| Beta | 1.14 |
| 11 Month Change | -14.53% |
| 3 Month Change | -86.81% |
| 1 Year Change | -75.94% |
| 33 Year Change | -91.32% |
| 5 Year Change | n/a |
| Change since IPO | -94.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9TD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 31.9% | -0.7% | 0.2% |
| 1Y | -75.9% | -17.2% | 8.5% |
Return vs Industry: 9TD underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 9TD underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 9TD volatility | |
|---|---|
| 9TD Average Weekly Movement | 45.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 9TD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9TD's weekly volatility has increased from 27% to 46% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 17 | Christer Valderhaug | www.arctic-bioscience.com |
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand worldwide.
Arctic Bioscience AS Fundamentals Summary
| 9TD fundamental statistics | |
|---|---|
| Market cap | €4.40m |
| Earnings (TTM) | -€4.19m |
| Revenue (TTM) | €2.76m |
1.6x
P/S Ratio-1.0x
P/E RatioIs 9TD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9TD income statement (TTM) | |
|---|---|
| Revenue | NOK 31.88m |
| Cost of Revenue | NOK 22.24m |
| Gross Profit | NOK 9.64m |
| Other Expenses | NOK 58.00m |
| Earnings | -NOK 48.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | 30.23% |
| Net Profit Margin | -151.72% |
| Debt/Equity Ratio | 0% |
How did 9TD perform over the long term?
See historical performance and comparison